Purine and lipid metabolism in rats with a rotenone model of Parkinson’s disease under the influence of methanindiazenone

Shtanova, L. Ya.; Veselsky, S.P.; Yanchuk, Petro I.; Tsymbalyuk, O. V.; Москвина, Виктория С.; Shablykina, O. V.; Moroz, O.F.; Vovkun, T.V.; Kravchenko, О.V.; Khilya, V. P.

doi:10.15407/fz68.06.018

Cited by 1 publication

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methanindiazenone treatment considerably enhanced motor activity in rats with Parkinson's-like symptoms, with behaviors aligning closely with healthy controls. Our prior study, which is part of this experiment, detailed these motor beha vior test results [19].…”

Section: Resultsmentioning

confidence: 99%

Benzodiazepinе derivative methanindiazenone modulates lipid metabolism in the liver of rats with rotenone-induced Parkinson’s syndrome

Shtanova,

Vesеlsky,

Yanchuk

et al. 2023

Fiziol Zh

Self Cite

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative condition for which the exact causes remain elusive, and no effective treatments currently exist. The pathogenesis of PD is believed to involve oxidative stress, mitochondrial dysfunction, and lipid metabolism disorders. A benzodiazepine derivative JM-20 has demonstrated protective effects on mitochondria in both neurons and peripheral tissues of rats with rotenoneinduced Parkinson’s syndrome (PS). This study aimed to analyze bile composition and assess the impact of a new benzodiazepine derivative, methanindiazenone, on lipid metabolism in the liver of rats subjected to the rotenone model of PS. The results indicated that, compared to the control group, bile concentration of phospholipids, cholesterol, cholesterol esters, and triglycerides decreased by 24.3, 26.2, 25.8, and 27.5%, respectively. With methanindiazenone treatment at doses of 0.5 and 1.0 mg/kg, all these metrics reverted to the control level. However, in the rotenone+methanindiazenone 2.0 mg/kg group, the levels of phospholipids, cholesterol, and cholesterol esters (except for triglycerides) surpassed the control values by 33, 28.1, 28.4 and 33.5%, respectively. Methanindiazenone positively impacted the motor behavior of rats with the rotenone model of PS and enhanced their survival rates. Therefore, at doses of 0.5 and 1.0 mg/kg, methanindiazenone not only improved lipid metabolism in the liver but also the overall well-being of rats with the rotenone model of PS. However, a 2 mg/kg dose of methanindiazenone displayed toxic effects, as seen from the increased content of phospholipids, cholesterol, and cholesterol esters in bile. Hence, methanindiazenone holds potential as a therapeutic agent for PS and possibly other neurodegenerative diseases related to lipid metabolism impairment, but its use should be limited to doses of 0.5 and 1.0 mg/kg.

show abstract

Section: Resultsmentioning

confidence: 99%